Better Mental Health
for More People

Scroll-Down-white

We are at a crisis point
in mental health provision.

Mental health and addiction (including alcohol), is the 5th leading cause of illness globally, affecting 20% of the world’s population.

Unlike other medical disciplines, psychiatry focuses on maintenance rather than cure, and symptom suppression rather than addressing the root causes of these illnesses.

The exception is Psychedelics and Psychedelic-Assisted Psychotherapy which have the potential to radically change mental health services and deliver significantly better patient outcomes.

About Awakn

Asset-44

Awakn Life Sciences is a clinical-biotech company researching, developing, and delivering evidenced-based psychedelic medicine to treat Addiction and other mental health conditions.

We are integrating psychedelic medicine into mainstream healthcare to enable better mental health for more people through Research, Clinics, and Ecosystems.

We have a dual strategic focus to develop and commercialise proprietary psychedelic therapies and New Molecular Entity drugs to treat Addiction and other mental health conditions in a chain of medical psychedelic clinics across the UK and EU.

Our goals are to be a global leader in the research of psychedelic therapies and New Molecular Entity drugs to treat Addiction, build the UK and EU’s leading chain of medical psychedelic clinics, and scale our reach through our Partnerships Ecosystem.

Why Awakn


Clear IP development pathway

• New Molecular Entity drugs
• Clinical trials


Global research leaders in psychedelic treatments

Dr. Ben Sessa led the world’s only MDMA and AUD study (BIMA) and Prof. Celia Morgan led the world’s leading Ketamine AUD study (KARE)


The leading scientific and medical team in the industry

Prof. David Nutt, Dr. Ben Sessa, Prof. Celia Morgan, Prof. Matt Johnson, Dr. Michael Mithoefer, and Ann Mithoefer


Strategic partnerships

Strategic partnerships with two leading UK universities for exclusive access to data and findings from recent clinical trials

➄ 
Scalable Revenue Streams

• Clinic revenue starting in Q1 2021
• Licensed Methods of Treatment 2022 onwards


Significant first mover advantage in UK and EU

400m people and US$19trn GDP

Divisions

Our business consists of three related and complementary divisions: Research, Digital, Clinics, and Ecosystems.

004

Awakn Research

Asset-44-1

Our team has led the research that has defined the psychedelic medicine industry, including: the Bristol Imperial MDMA for Alcoholism (BIMA) study and the Ketamine for Reduction of Alcoholic Relapse (KARE).

We have a portfolio of drug development and clinical trials planned and initiated focused on treating addiction.

Awakn Clinics

Asset-44

We provide hope for those whom the status quo is not working by combining the proven therapeutic potential of ketamine with psychotherapy to treat Addiction, Anxiety, Depression, and PTSD.

• Bristol Q1 2021
• London 1 & Manchester 2021
• London 2, Birmingham, Dublin (Ireland) 2022
• Continental Europe 2023+

awakn-1
009

Awakn Partnerships Ecosystems

Asset-44-1-2

Scale our reach beyond our core territories through licencing to enable addiction treatment practitioners deliver the Awakn methodology:

Protocols & Therapy

• Training
• Clinic Design Best Practice 
• Data, Analytics, Insights


Scientific Advisory Team

Our pioneering team is made up of some of the leading clinical researchers, scientific minds and clinical experts in the global industry

davidnutt-1

Prof. David Nutt

CHAIR

bensessa

Dr. Ben Sessa

CHIEF MEDICAL OFFICER

celiamorgan

Prof. Celia Morgan

HEAD OF KETAMINE-ASSISTED 
PSYCHOTHERAPY FOR ALCOHOL 
USE DISORDER PRACTICE

michael-mithoefer

Dr. Michael Mithoefer

ADVISOR

annmithoefer

Ann Mithoefer, BSN

ADVISOR

matthewjohnson

Prof. Matthew W.  Johnson

ADVISOR

Leadership Team

bensessa

Dr. Ben Sessa

CHIEF MEDICAL OFFICER

celiamorgan

Prof. Celia Morgan

HEAD OF KETAMINE-ASSISTED 
PSYCHOTHERAPY FOR ALCOHOL 
USE DISORDER PRACTICE

lauriehigbed

Dr. Laurie Higbed

LEAD PSYCHOLOGIST

georgescorsis

George Scorsis

CHAIR

anthonytennison

Anthony Tennyson

CHIEF EXECUTIVE OFFICER

jamescollins-1

James Collins

CHIEF OPERATING OFFICER

shaunmcnutty

Dr. Shaun McNulty

CHIEF SCIENCE OFFICER

jonathanheld

Jonathan Held

CHIEF FINANCIAL OFFICER

Latest News

A female pharmacist is examining a vial in a pharmacy

09.03.2021.

Awakn Acquires Proprietary Next Generation MDMA and Ketamine Data from Prof. David Nutt

Awakn Logo and NEO Exchange logo

04.03.2021.

Awakn announces intent to pursue qualifying transaction in preparation for listing on the NEO exchange in Canada

Picture of the University of Exeter in black and white

02.03.2021.

Awakn acquires IP from a Phase II KAP Trial for AUD from the University of Exeter

ben2

19.02.2021.

Dr. Ben Sessa about the World’s First ‘MDMA in Alcohol Use Disorder’ Clinical Trial

james_collins

25.01.2021.

Awakn Appoints James Collins as Chief Operating Officer

Video Resources

alcohol_study

Dr. Ben Sessa live on Euronews

nutt

Prof. David Nutt: TEDx

Ben

Dr. Ben Sessa: TEDx

oo5

Revealing the Mind: The Promise of Psychedelics

Contact

Awakn_logo_descriptor-02-1

MAIN OFFICE
Suite 200, 366 Bay St,
Toronto, Ontario, M5H 4B2, Canada


UK OFFICE
1 Regent Street,
Bristol, BS8 4HW, United Kingdom

For all enquiries, complete the form and we’ll be in touch.

© 2021 Awakn Life Sciences Inc      |      Privacy Policy      |      Appropriate Use Policy